Bio-Techne Corporation vs Alkermes plc: Strategic Focus on R&D Spending

R&D Spending Trends: Bio-Techne vs Alkermes

__timestamp	Alkermes plc	Bio-Techne Corporation
Wednesday, January 1, 2014	7753000	30945000
Thursday, January 1, 2015	4019000	40853000
Friday, January 1, 2016	2301000	45187000
Sunday, January 1, 2017	7232000	53514000
Monday, January 1, 2018	68895000	55329000
Tuesday, January 1, 2019	52816000	62413000
Wednesday, January 1, 2020	1946000	65192000
Friday, January 1, 2021	1020000	70603000
Saturday, January 1, 2022	393842000	87140000
Sunday, January 1, 2023	270806000	92493000
Monday, January 1, 2024	245326000	96664000

Unveiling the hidden dimensions of data

Strategic Focus on R&D Spending: Bio-Techne Corporation vs Alkermes plc

In the competitive landscape of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Bio-Techne Corporation and Alkermes plc have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, Bio-Techne consistently increased its R&D expenses, peaking at approximately $92 million in 2023, reflecting a steady growth of over 200% from 2014. In contrast, Alkermes plc exhibited a more volatile pattern, with a significant spike in 2022, where R&D spending surged to nearly $394 million, a dramatic increase from previous years. This fluctuation suggests a strategic pivot or a response to market demands. As we look to the future, these spending patterns may offer insights into each company's strategic priorities and potential market innovations.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025